GET DAILY SIGNALSMobia Medical (MOBI) Delivers 73% Q3 Revenue Growth and Raises Full-Year Guidance
Key Takeaways
- Third-quarter 2026 revenue climbed 73% year over year to $15.6 million, surpassing the consensus estimate of roughly $15.35 million.
- Net loss widened to $17.3 million, or $0.52 per diluted share, compared with $11.4 million, or $13.31 per share, in the prior-year period.
- Gross margin improved to 83.2% from 79.6% a year earlier, helped by lower freight, tariff, and inventory write-off costs.
- Mobia Medical sold approximately 425 Vivistim units and expanded to 40 average active territories, up 78% year over year.
- Full-year 2026 revenue guidance was raised to $57.0 million–$57.5 million, implying roughly 78%–79% growth.
- Cash and cash equivalents stood at $160.7 million as of September 30, 2026.
Earnings Context and Why It Matters
MOBI, formerly MicroTransponder Inc., is a commercial-stage medical device company focused on stroke rehabilitation. Its flagship product, the Vivistim Paired VNS (Vagus Nerve Stimulation) System, is the first FDA-approved therapy of its kind for chronic ischemic stroke survivors with moderate-to-severe upper extremity impairment. The company completed its initial public offering (IPO) in May 2026, making these quarterly results an important early test of its commercial ramp. With stroke remaining a leading cause of long-term disability in the U.S., investors are watching unit sales, territory expansion, gross margin, and cash burn closely to gauge whether Vivistim adoption can scale efficiently toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
MOBI reported third-quarter 2026 revenue of $15.6 million, a 73% increase from $9.0 million in the same period last year. The result came in ahead of the consensus estimate of approximately $15.35 million and was driven by broader adoption of Vivistim therapy across both new and existing programs, with roughly 425 units sold in the quarter.
Gross margin expanded to 83.2% from 79.6% a year earlier, primarily reflecting lower freight and tariff costs recognized in cost of goods sold as a percentage of sales, as well as lower inventory write-offs. Operating expenses rose to $31.5 million from $18.4 million, reflecting continued investment in the company's commercial organization.
The company posted a net loss of $17.3 million, or $0.52 per diluted share, compared with a net loss of $11.4 million, or $13.31 per share, in the prior-year period. The improvement in per-share loss largely reflects the significant increase in shares outstanding following the May 2026 IPO and the related conversion of preferred stock and convertible notes. The reported loss was wider than the analyst consensus of roughly $0.44 per share, even as revenue topped expectations.
Management also raised its full-year 2026 revenue guidance to a range of $57.0 million to $57.5 million, up from prior guidance of $54.0 million to $56.0 million, implying approximately 78%–79% growth over 2025.
Market Reaction and Investor Sentiment
Despite the revenue beat and raised guidance, MOBI shares fell sharply in after-hours trading following the November 5, 2026 report, dropping roughly 18% to the $9.17 level. The pullback suggests investors weighed the wider-than-expected net loss and elevated operating expenses against the strong top-line momentum. Sentiment heading into the print had been broadly positive, with the stock recently trading above its 50-day moving average and analysts maintaining Buy ratings with price targets well above the prevailing share price. The post-earnings decline highlights how a growing but still loss-making commercial-stage company can be judged as much on profitability trajectory and cash burn as on revenue growth. From what I see, this reaction underscores the importance of monitoring expense trends closely.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch whether Mobia Medical can sustain its revenue growth rate while demonstrating operating leverage. Management has indicated comfort with a 78%–79% year-over-year growth pace for 2026, and the raised guidance reflects confidence in momentum coming out of the third quarter.
Territory expansion remains a central metric. The company reached 40 average active territories in Q3 2026, an increase of 78% year over year, and management has previously described four to five net territory additions per quarter as a comfortable range. Continued expansion, combined with improving productivity in existing territories, will be key to sustaining unit sales growth.
Margins and cash are also in focus. Gross margin in the low-80% range appears durable, but rising operating expenses tied to commercialization mean the path to profitability depends on revenue scaling faster than spending. With $160.7 million in cash as of September 30, 2026, the company has meaningful runway, though investors will monitor quarterly cash burn closely.
Finally, clinical and regulatory milestones could act as catalysts. Management has pointed to a $30 billion total addressable market (TAM) and expects to publish its GRASP registry, or the first portion of it, within 2027, which could provide additional clinical evidence to support broader adoption of Vivistim therapy.
Using Tickeron AI Tools in My Research
I often rely on Tickeron’s AI Screener when evaluating names in the medical device space. It allows me to quickly scan for comparable companies based on fundamentals, technical patterns, and performance metrics, helping me put MOBI’s results into broader context without spending hours on manual analysis. This tool has become a regular part of how I review earnings and identify related opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MOBI saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for MOBI moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 5 similar instances where the indicator exited the overbought zone. In 5 of the 5 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MOBI entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MOBI as a result. In 4 of 5 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for MOBI just turned positive on October 19, 2026. Looking at past instances where MOBI's MACD turned positive, the stock continued to rise in 2 of 2 cases over the following month. The odds of a continued upward trend are 90%.
MOBI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOBI advanced for three days, in 20 of 22 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.158) is normal, around the industry mean (4.137). P/E Ratio (-5.807) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (7.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. MOBI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement